Clinical Drug Investigation

, Volume 33, Issue 11, pp 855–860

Factors Associated with the Length of Remission of Psoriasis Vulgaris

Short Communication



Cardiovascular risk factors are found with significantly high frequency in psoriatic patients. Periods of remission and reactivation of lesions are common in psoriasis.


Considering the association of chronic inflammation with the atherogenic process, we aimed to search for a possible relationship between the lipid profile, adipokine levels and body mass index (BMI) at the end of a successful treatment for psoriasis, and the length of remission of psoriasis.


Forty-three patients were clinically and analytically studied after a successful treatment [as shown by Psoriasis Area and Severity Index (PASI)]—nine treated with topical agents, 17 with narrow-band UV light B (NB-UVB) and 17 with psoralen plus UVA-and were followed to record the length of remission.


The length of psoriasis remission correlated negatively and significantly with cholesterol levels, which correlated significantly and positively with C-reactive protein (CRP). In multiple linear regression analysis, cholesterol, CRP, PASI and BMI were associated with the length of remission. Patients with cholesterol levels <200 mg/dL (n = 13) presented a significantly longer remission, lower BMI and triglycerides values, and a trend towards lower PASI and CRP values than those with high cholesterol (n = 30). Considering patients according to the treatment used, cholesterol was also associated with length of remission, especially for patients treated with NB-UVB and topical therapy.


Psoriasis patients with the highest cholesterol levels presented higher BMIs, triglycerides levels and shorter remission periods. Our data suggest that the identification of potentially treatable conditions, such as dyslipidaemia and obesity, and their adequate treatment may benefit psoriasis patients by increasing the length of remission of the disease.


  1. 1.
    Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta. 2001;303:33–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54:614–21.PubMedCrossRefGoogle Scholar
  3. 3.
    Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol. 2007;157:649–55.PubMedCrossRefGoogle Scholar
  4. 4.
    Coimbra S, Oliveira H, Reis F, et al. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatol Sci. 2009;55:202–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Coimbra S, Oliveira H, Reis F, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol. 2010;24:789–96.PubMedCrossRefGoogle Scholar
  6. 6.
    Coimbra S, Oliveira H, Reis F, et al. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study. Am J Clin Dermatol. 2010;11:423–32.PubMedCrossRefGoogle Scholar
  7. 7.
    Dreiher J, Weitzman D, Davidovici B, et al. Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol. 2008;88:561–5.PubMedGoogle Scholar
  8. 8.
    Friedewald VE Jr, Cather JC, Gordon KB, et al. The editor’s roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol. 2008;101:1119–26.PubMedCrossRefGoogle Scholar
  9. 9.
    Sakai R, Matsui S, Fukushima M, et al. Prognostic factor analysis for plaque psoriasis. Dermatology. 2005;211:103–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol. 2004;18:180–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol. 2004;150:917–28.PubMedCrossRefGoogle Scholar
  12. 12.
    Boekholdt SM, Hack CE, Sandhu MS, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993–2003. Atherosclerosis. 2006;187:415–22.PubMedCrossRefGoogle Scholar
  13. 13.
    Coimbra S, Oliveira H, Belo L, et al. Principal determinants of the length of remission of psoriasis vulgaris after topical, NB-UVB, and PUVA therapy: a follow-up study. Am J Clin Dermatol. 2013;14:49–53.PubMedCrossRefGoogle Scholar
  14. 14.
    Coimbra S, Oliveira H, Reis F, et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol. 2010;24:1386–94.PubMedCrossRefGoogle Scholar
  15. 15.
    Panagiotakos DB, Pitsavos C, Yannakoulia M, et al. The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis. 2005;183:308–15.PubMedCrossRefGoogle Scholar
  16. 16.
    Naldi L, Addis A, Chimenti S, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology. 2008;217:365–73.PubMedCrossRefGoogle Scholar
  17. 17.
    Bardazzi F, Balestri R, Baldi E, et al. Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy. Dermatol Ther. 2010;23(Suppl 1):S14–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Franssen R, Monajemi H, Stroes ES, Kastelein JJ. Obesity and dyslipidemia. Med Clin North Am. 2011;95:893–902.PubMedCrossRefGoogle Scholar
  19. 19.
    Rana JS, Nieuwdorp M, Jukema JW, Kastelein JJ. Cardiovascular metabolic syndrome—an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab. 2007;9:218–32.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Susana Coimbra
    • 1
    • 2
  • Hugo Oliveira
    • 3
  • Américo Figueiredo
    • 3
  • Petronila Rocha-Pereira
    • 1
    • 4
  • Alice Santos-Silva
    • 1
    • 5
  1. 1.Instituto de Biologia Molecular e Celular (IBMC)Universidade do PortoPortoPortugal
  2. 2.CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da SaúdeGandra-PRDPortugal
  3. 3.Serviço de Dermatologia, Centro Hospitalar e Universitário de CoimbraUniversidade de CoimbraCoimbraPortugal
  4. 4.Centro de Investigação em Ciências da Saúde (CICS)Universidade da Beira InteriorCovilhãPortugal
  5. 5.Laboratório de Bioquímica, Departamento de Ciências Biológicas, Faculdade de Farmácia (FFUP)Universidade do PortoPortoPortugal

Personalised recommendations